TNB-383B is a laboratory-created antibody that facilitates the interaction between immune cells and cancer cells, resulting in a more targeted immune response. This antibody specifically targets the B-cell maturation antigen found in myeloma cells and the CD3 surface receptor present in T-cells, acting as a link between the two. The initial trial of TNB-383B in humans, conducted in collaboration with AbbVie, aims to assess the safety and tolerability of the compound, as well as various pharmacological characteristics including its peak concentration in the bloodstream and its half-life (the duration for a dose to decrease to half of its initial amount).
Specifications
Catalog Number:
KB-1350
Antibodies Name:
TNB383B-CD3-hIgG1
Host Cell Line:
EXPI-CHO
Target:
CD3
Species Reactivity:
Human
Application:
ELISA | FACS
Purification Method:
Affinity purified
Concentration:
>2mg/mL
Purity:
>95% by SDS-PAGE and SEC-HPLC
Endotoxin Level:
<0.5 EU/mg as determined by the LAL method
Sterility:
0.2μm filtered
Formulation:
20mM sodium citrate,150mM NaCl, pH5.5
Storage:
Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.
Bio Safety Level:
1
Validation:
SDS-PAGE | SEC-HPLC | ELISA | FACS
Characterization
Application
References
1.A Phase 1 First-in-Human Study of Tnb-383B, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in Patients with Relapsed/Refractory Multiple Myeloma
2.A Study of TNB-383B in Subjects With Relapsed or Refractory Multiple Myeloma
